Patients with suspected coronavirus disease 2019 (COVID-19) can infect others at any time, including during transfer and transport. COVID-19 is a new infectious disease that requires contact and droplet precautions; lapses in infection prevention and control (IPC) can easily happen at vulnerable mom...ents such as during transfer. This guide aims to identify key steps to prepare the community and health system response to ensure IPC is maintained during transfer and transport. This guide is intended for personnel involved in coordinating and performing transfer and transport of patients with suspected COVID-19 requiring hospital care.
more
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of HIV/AIDS Prevention
Accessed: 03.09.2019
Tuberculosis treatment failure results in increased risk of morbidity, drug resistance, transmission and mortality. There are few data about tuberculosis treatment outcomes in Burkina Faso. The current study investigated the factors associated with tuberculosis treatment failure in the central east ...health region of Burkina Faso.
more
Also available in Arabic, German, Greek, Italian, Croatian, Polish, Romanian, Russian, Serbian, Spanish, Turkish and Vietnamese. Other language versions can be found on the website of the German liver foundation: http://www.deutsche-leberstiftung.de/hilfe/informationsmaterialien/faltblätter.
Medicina (Kaunas) 2013;49(7):335-40
Evaluation report
April 2013
Evaluation report
This report is part of the overall Ukrainian National AIDS programme evaluation conducted
in September 2012
Q 2: How long should treatment with antidepressants continue in adults with depressive episode/disorder?
Supplement article
The Journal of Infectious Diseases® 2017;216(S7):S675–8
DOI: 10.1093/infdis/jix368
Finding the Missing Tuberculosis Patients • JID 2017:216 (Suppl 7) • S675
Downloaded from https://academic.oup.com/jid/article-abstract/216/suppl_7/S675/4595547
by guest on 13 Nove...mber 2017
more
NICE guideline
Published: 23 May 2017
These updates include shorter novel 6-month all-oral regimens for the treatment of multidrug- and rifampicin-resistant TB (MDR/RR-TB), with or without additional resistance to fluoroquinolones (pre-XDR-TB) as well as an alternative 9-month all-oral regimen for the treatment of MDR/RR-TB.
This Ra...pid Communication is released in advance of updated WHO consolidated guidelines expected later in 2022, to inform national TB programmes and other stakeholders of key changes in the treatment of DR-TB and to allow for rapid transition and planning at the country level.
more
4th edition. This is fourth edition of Treatment of tuberculosis: guidelines, adhering fully to the new WHO process for evidence-based guidelines. Several important recommendations are being promoted in this new edition